

# Hemophilia Products – Coagulation Factor XIII A-subunit: Tretten®

(Intravenous)

Effective date: 10/1/2019

Review date: 1/29/2020, 7/15/2021, 6/16/2022, 6/22/2023, 12/07/2023, 01/04/2024

Scope: Medicaid\*, Commercial\*, Medicare-Medicaid Plan (MMP)
\*(Medication only available on the Medical Benefit)

## I. Length of Authorization

Unless otherwise specified\*, the initial authorization will be provided for 3 months and may be renewed.

<u>Note</u>: The cumulative amount of medication the patient has on-hand will be taken into account for authorizations. Up to 5 'on-hand' doses for the treatment of acute bleeding episodes will be permitted at the time of the authorization request.

\* Initial and renewal authorization periods may vary by specific covered indication

## II. Dosing Limits

- Quantity Limit (max daily dose) [Pharmacy Benefit]:
- Tretten 2,000-3,125 IU vial: 2 vials per 28-day supply
- Max Units (per dose and over time) [Medical Benefit]:
  - 4,025 billable units per 28 day supply

# III. Summary of Evidence

Clinical trials support the efficacy and safety of Tretten in managing bleeding episodes and preventing bleeding complications in patients with congenital Factor XIII deficiency. This therapy provides exogenous Factor XIII activity, promoting stable fibrin clot formation and reducing the risk of spontaneous or traumatic bleeds. The most common adverse reactions reported in the clinical trials were headache, pain in the extremities, injection site pain, D dimer increase.

## IV. Initial Approval Criteria

#### Hemophilia Management Program

Requirements for half-life study and inhibitor tests are a part of the hemophilia management program. This information is not meant to replace clinical decision making when initiating or modifying medication therapy and should only be used as a guide.

#### A. Tretten

Coverage is provided in the following conditions:



• MMP members who have previously received this medication within the past 365 days are not subject to Step Therapy Requirements.

Congenital Factor XIII A-subunit deficiency  $\dagger \Phi$  Diagnosis of congenital factor XIII A-subunit deficiency has been confirmed by blood coagulation testing; **AND** 

Used for routine prophylaxis of bleeding

## Hemophilia Management Program

- If the request is for routine prophylaxis and the requested dose exceeds dosing limits under part II, a half-life study should be performed to determine the appropriate dose and dosing interval.
- For members with a BMI ≥ 30, a half-life study should be performed to determine the appropriate dose and dosing interval.
- For minimally treated patients (< 50 exposure days to factor products) previously receiving a different factor product, inhibitor testing is required at baseline, then at every comprehensive care visit (yearly for the mild and moderate patients, semi-annually for the severe patients).

† FDA Approved Indication(s); ‡ Compendia Recommended Indication(s); • Orphan Drug

# V. Dispensing Requirements for Rendering Providers (Hemophilia Management Program)

- Prescriptions cannot be filled without an expressed need from the patient, caregiver or prescribing practitioner. Auto-filling is not allowed.
- Monthly, rendering provider must submit for authorization of dispensing quantity before delivering factor product. Information submitted must include:
  - Original prescription information, requested amount to be dispensed, vial sizes available to be ordered from the manufacturer, and patient clinical history (including patient product inventory and bleed history)
  - Factor dose should not exceed +1% of the prescribed dose and a maximum of three vials may be dispensed per dose. If unable to provide factor dosing within the required threshold, below the required threshold, the lowest possible dose able to be achieved above +1% should be dispensed. Prescribed dose should not be increased to meet assay management requirements.
- The cumulative amount of medication(s) the patient has on-hand should be taken into account when dispensing factor product. Patients should not have more than 5 extra doses on-hand for the treatment of acute bleeding episodes.
- Dispensing requirements for renderings providers are a part of the hemophilia management program. This
  information is not meant to replace clinical decision making when initiating or modifying medication therapy
  and should only be used as a guide.

## VI. Renewal Criteria

Coverage may be renewed based upon the following criteria:



- Patient continues to meet criteria identified in section III; AND
- Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include the following: symptoms of allergic-anaphylactic reactions (anaphylaxis, dyspnea, rash, urticaria, tightness of the chest, hypotension, etc.), thromboembolic events (thromboembolism, pulmonary embolism), development of neutralizing antibodies (inhibitors), etc.; AND
- Any increases in dose must be supported by an acceptable clinical rationale (i.e., weight gain, half-life study results, increase in breakthrough bleeding when patient is fully adherent to therapy, etc.); **AND**
- The cumulative amount of medication(s) the patient has on-hand will be taken into account when authorizing. The authorization will allow up to 5 doses on-hand for the treatment of acute bleeding episodes as needed for the duration of the authorization; **AND**

#### Routine prophylaxis of bleeding episodes

- Renewals will be approved for a 12 month authorization period; AND
- Patient has demonstrated a beneficial response to therapy (i.e., the frequency of bleeding episodes has decreased from pre-treatment baseline)

# VII. Dosage/Administration

Indication	Dose
Routine prophylaxis for bleeding congenital factor XIII A-subunit deficiency	Administer 35 international units (IU) per kilogram body weight once monthly to achieve a target trough level of FXIII activity at or above 10% using a validated assay.


# VIII. Billing Code/Availability Information

#### **HCPCS & NDC:**

Drug	Manufacturer	J-Code	1 Billable Unit Equiv.	Vial Size	NDC
Tretten	Novo Nordisk	J7181	1 IU	Unassigned size	00169-7013

#### IX. References

- 1. Tretten [package insert]. Bagsvaerd, Denmark; Novo Nordisk; June 2020. Accessed November 2023.
- MASAC RECOMMENDATIONS CONCERNING PRODUCTS LICENSED FOR THE TREATMENT OF HEMOPHILIA AND OTHER BLEEDING DISORDERS. 2016 National Hemophilia Foundation. MASAC Document #249; October 2016. Available at: http://www.hemophilia.org. Accessed January 2019.
- 3. Guidelines for the Management of Hemophilia. 2<sup>nd</sup> Edition. World Federation of Hemophilia. 2013. Available at: https://www1.wfh.org/publication/files/pdf-1472.pdf. Accessed January 2019.





- 4. Annual Review of Factor Replacement Products. Oklahoma Health Care Authority Review Board. Updated April 2016. Access January 2019.
- 5. Graham A1, Jaworski K. Pharmacokinetic analysis of anti-hemophilic factor in the obese patient. Haemophilia. 2014 Mar;20(2):226-9.
- 6. Croteau SE1, Neufeld EJ. Transition considerations for extended half-life factor products. Haemophilia. 2015 May;21(3):285-8.
- 7. Mingot-Castellano, et al. Application of Pharmacokinetics Programs in Optimization of Haemostatic Treatment in Severe Hemophilia a Patients: Changes in Consumption, Clinical Outcomes and Quality of Life. Blood. 2014 December; 124 (21).
- 8. MASAC RECOMMENDATION CONCERNING PROPHYLAXIS. 2016 National Hemophilia Foundation. MASAC Document #241; February 2016. Available at: http://www.hemophilia.org. Accessed January 2019.
- 9. First Coast Service Options, Inc. Local Coverage Determination (LCD): Hemophilia Clotting Factors (L33684). Centers for Medicare & Medicaid Services, Inc. Updated on 01/04/2019 with effective date 01/01/2019. Accessed January 2019.
- 10. Novitas Solutions, Inc. Local Coverage Determination (LCD): Hemophilia Clotting Factors (L35111). Centers for Medicare & Medicaid Services, Inc. Updated on 01/19/2018 with effective date 01/01/2018. Accessed January 2019.

# Appendix 1 – Covered Diagnosis Codes

ICD-10	ICD-10 Description
D68.2	Hereditary deficiency of other clotting factors



## Appendix 2 – Centers for Medicare and Medicaid Services (CMS)

Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determination (NCD), Local Coverage Articles (LCAs), and Local Coverage Determinations (LCDs) may exist and compliance with these policies is required where applicable. They can be found at: <a href="https://www.cms.gov/medicare-coverage-database/search.aspx">https://www.cms.gov/medicare-coverage-database/search.aspx</a>. Additional indications may be covered at the discretion of the health plan.

Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCA/LCD/)

Jurisdiction(s): J,M	NCD/LCD Document (s): A56065
----------------------	------------------------------

https://www.cms.gov/medicare-coverage-database/new-search/search-


results.aspx?keyword=a56065&areaId=all&docType=NCA%2CCAL%2CNCD%2CMEDCAC%2CTA%2CMCD%2 C6%2C3%2C5%2C1%2CF%2CP

Jurisdiction(s): H,L	NCD/LCD Document (s): A56433
o ar isarchomes, ii.n	HACDIDOD DOCUMENT (8), PROFESS

https://www.cms.gov/medicare-coverage-database/new-search/search-

results.aspx?keyword=a56433&areaId=all&docType=NCA%2CCAL%2CNCD%2CMEDCAC%2CTA%2CMCD%2C6%2C3%2C5%2C1%2CF%2CP

Medicare Part B Administrative Contractor (MAC) Jurisdictions			
Jurisdiction	Applicable State/US Territory	Contractor	
E (1)	CA, HI, NV, AS, GU, CNMI	Noridian Healthcare Solutions, LLC	
F (2 & 3)	AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ	Noridian Healthcare Solutions, LLC	
5	KS, NE, IA, MO	Wisconsin Physicians Service Insurance Corp (WPS)	
6	MN, WI, IL	National Government Services, Inc. (NGS)	
H (4 & 7)	LA, AR, MS, TX, OK, CO, NM	Novitas Solutions, Inc.	
8	MI, IN	Wisconsin Physicians Service Insurance Corp (WPS)	
N (9)	FL, PR, VI	First Coast Service Options, Inc.	





Medicare Part B Administrative Contractor (MAC) Jurisdictions				
Jurisdiction	Applicable State/US Territory	Contractor		
J (10)	TN, GA, AL	Palmetto GBA, LLC		
M (11)	NC, SC, WV, VA (excluding below)	Palmetto GBA, LLC		
	DE, MD, PA, NJ, DC (includes Arlington & Fairfax counties and the city of Alexandria in VA)	Novitas Solutions, Inc.		
K (13 & 14)	NY, CT, MA, RI, VT, ME, NH	National Government Services, Inc. (NGS)		
15	КҮ, ОН	CGS Administrators, LLC		

#### Policy Rationale:

Tretten was reviewed by the Neighborhood Health Plan of Rhode Island Pharmacy & Therapeutics (P&T) Committee. Neighborhood adopted the following clinical coverage criteria to ensure that its members use Tretten according to Food and Drug Administration (FDA) approved labeling and/or relevant clinical literature. Neighborhood worked with network prescribers and pharmacists to draft these criteria. These criteria will help ensure its members are using this drug for a medically accepted indication, while minimizing the risk for adverse effects and ensuring more cost-effective options are used first, if applicable and appropriate. For INTEGRITY (Medicare-Medicaid Plan) members, these coverage criteria will only apply in the absence of National Coverage Determination (NCD) or Local Coverage Determination (LCD) criteria. Neighborhood will give individual consideration to each request it reviews based on the information submitted by the prescriber and other information available to the plan.